+34 9340006100 -ext. 437807-info@nanbiosis.com

Nanbiosis

You are here : Home / Archive for "nanomedicine"

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB

Order request
U1 PPP-Insect cells-Baculovirus as cell factoriesU1 PPP-Insect cells-Baculovirus as cell factories
U1 PPP-7L Bioreactor for protein productionU1 PPP-7L Bioreactor for protein production
U1 PPP–AKTA Purifier equipment for protein purificationU1 PPP–AKTA Purifier equipment for protein purification

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit has implemented the ISO9001 certification forstandard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U1. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017		 Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
BIO2013-41019-P ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS MINECO Participant
2014SGR-132 Basic and Applied Microbiology AGAUR Participant
BIO2016-76063-R DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES MINECO Working package
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant
Marato 416/C/2030TV32013-132031 Genotoxic nanoparticles targeting colorectal cancer stem cells Marato TV3 Participant

Publications


2016

  • Corchero J.L.. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

28 Sep

Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund

September 27th 2022 – Nanoligent SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by i&i Biotech Fund I (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund. i&i Bio joined previous Nanoligent investors, Italian Angels for Growth, the largest network of business angels in Italy, and AVANTECA Partners, a Swiss privately held[...]

16 Aug

Two NANBIOSIS Units of CIBER-BBN at UAB, one of the 300 best universities in the world, according the Shanghai Ranking

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings Two of NANBIOSIS Units created by UAB and CIBER-BBN are part of this university: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Mercedes Marquez, offer an “tailored” service for the design,[...]

25 Jun

How engineered protein helps Nanomedicine againts Cancer

The use of protein nanoparticles as biomaterials have been rising in recent years due to their characteristics: high biocompatibility, structural versatility, biodegradability and plasticity of design. We can later incorporate peptide ligands for specific targeting as fusion proteins and use these nanoparticles for targeted nanomedicine. However, not all proteins can be used as scaffolds for targeted drug delivery, as they need to meet certain criteria. First, it is crucial that the proteins used as a scaffold allow site-specific drug conjugation. The stability and proteolysis resistance of these proteins is also important to remain assembled during the bloodstream circulation. In addition,[...]

02 May

Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé

During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Nanoligent, whoes founders are leaders of NANBIOSIS units, raises €1M in Series Seed financing

Barcelona, Spain – Milan, Italy, February 3rd, 2022 – Nanoligent SL, a biotech company specialized in the development of nanotechnology-based cancer treatments, today announces the completion of the first closing of a Seed financing round of €1M. The round has been led by members of Italian Angels for Growth, the largest network of business angels in Italy, through the investment vehicle Nanolinvest, and AVANTECA Partners, a Swiss privately held asset management firm, both specialized in supporting innovative early-stage life-science companies primarily in Europe. An equity campaign, is still ongoing on Doorway, an online investment platform, thus promising to provide additional funding[...]

11 Jan

The activity of Peptide T22 as antimicrobial drug opens new possibilities for the local control of bacterial infections related to tumors

Researchers of NANBIOSIS Units 1 and 18, from CIBER-BBN at the Institut de Biotecnologia i de Biomedicina (IBB-UAB) and the Institut de Recerca Sant Pau (IIB-Sant Pau) presents the finding of a significant antimicrobial activity in the targeting peptide T22, which is used for antitumor therapy directed against CXCR4 + stem cells, with clinical interest in more than 20 types of human cancer, including colorectal cancer. The study describes how said activity has a significant effect on several bacterial species of clinical importance: “we have detected antimicrobial activity associated with T22 and inhibition of biofilm formation on Escherichia coli, Staphylococcus[...]

18 Apr

Collaboration of two NANBIOSIS units in the Valorisation Project “ADVERT”

The Project ADVERT (Advanced Extracellular Vesicles for Enzyme Replacement Therapy) is a research valorisation project recently granted by CIBER. The project pursues to advance the development of extracellular vesicles as treatments for lysosomal diseases, specially to bring new therapies to treat FABRY disease. The ADVERT Project will count on the active particpation of two NANBIOSIS units of CIBER-BBN: Unit 20 of the ICTS NANBIOSIS at Vall d’Ebrón Hospital, led by Ibane Abasolo, who coordinates the project. Unit 1 Protein Production Platform (PPP), at the IBB-UAB, led by Neus Ferrer, throught the coordination in the project of José Luis Corchero. T[...]

U1-Protein Production Platform - PPP
• Read More

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone
Ciber bbn

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dra. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request
U2 CAbS-Monoclonal antibody developmentU2 CAbS-Monoclonal antibody development
U2 CAbS-Hapten synthesisU2 CAbS-Hapten synthesis
U2 CAbS-Antibody purificationU2 CAbS-Antibody purification

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U2. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
PIE1400061 Molecular links between diabetes and neurodegenerative diseases ISCIII Oberver
2014SGR1484 Consolidated Research Group Generalitat de Catalunya Participant
FP7-614168 Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP) European Commission Oberver
CI16-00031 Caixa Impulse A new approach for the detection of Pseudomonas aeruginosa CaixaBank Participant
MSCA-ITN2015-675412 New Diagnostics for Infectious Diseases European Commission Participant
TECCTP15-1-0011 Ajuda acreditació Tecnio del grup Nb4D ACCIÓ: Generalitat de Catalunya Others

Publications


2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

15 May

New look of Nb4D – CAbS (NANBIOSIS U2) “Revolutionising Diagnosis”

Nb4D has a new look on line! Nb4D Group (of IQAC-CSIC and CIBER-BBN) has lunched a new website “Revolutionsising Diagnosis“ with the aim to facilitate a faster and easier navigation througth their “pioneering research to develop new diagnostic and therapeutic approaches” and their solutions and expertise to help researchers and companies. Antibodies, bioreceptors, hapten design and synthesis, immunoanalytical method development, new ivd tools, surface functionalization, therapeutic antibodies and much more knowledge and expertise revolutionising diagnosis. The new website contains a page for CAbS-NANBIOSIS. Custom Antibody Service (CAbS), unit 2 of the ICTS NANBIOSIS[...]

28 Feb

Rare diseases international day 2023: some NANBIOSIS contributions

Today is the international day of rare diseases, a day to raise awareness and instigate change for people living with a rare disease. From NANBIOSIS we want to sume to this celebration and higtligh our commitment to helping people with rare diseases through research. Dr. Ibane Abasolo, Scientific Director of NANBIOSIS U20, was at the WORLDSymposia conference last week in Orlando (FL, USA), where the latest advances in preclinical study and clinic of lysosomal storage diseases were explained. There, she presented the results obtained in the Smart4Fabry project coordinated by the CIBER-BBN where nanoliposomes were developed for the treatment of[...]

27 Feb

New method for the detection of RNA viruses such as SARS-CoV-2

Several CIBER-BBN groups at the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Institute of Nanoscience and Materials of Aragon (INMA) —a joint institute of the CSIC and the University of Zaragoza (UNIZAR)— have developed a new method for detecting RNA viruses based on the technology of using probes that form triplex structures. This innovative methodology opens up new options to detect viruses such as SARS-CoV-2, the influenza A (H1N1) virus or the respiratory syncytial virus (RSV), a pathogen that affects newborns and requires differential diagnostic care. This[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

19 Oct

The first TECNIO Conference and NANBIOSIS’ researchers participation

More than 200 people attended the first edition of the TECNIO Conference that took place on October 19th, 2022 in Girona. Outstanding experts from research groups, companies and the Catalan administration discussed the model of technological sovereignty that Catalonia needs to generate high-impact innovation. As far as Nora Ventosa, President of the TECNIO Association and Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit (from CIBER-BBN and IQAC): “Political management is the key to ensure that the path of transference follows a high speed train” Researchers of NANBIOSIS U2 Custom Antibody Service (CAbS) – Nb4D Group from CIBER-BBN and[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

28 Dec

New results evidence new biomarkers for early diagnosis of P. aeruginosa infections

Pseudomonas aeruginosa is a common multidrug-resistant pathogen that causes acute and chronic infections. However, P. aeruginosa, as many other bacterial species, has developed resistance to antibiotics being difficult to treat. For this reason diagnostic methods allowing detection at early  stages of the infection are required  and, therefore, efficient biomarkers of infection are very helpful. These fast diagnosis will help on the subsequent therapeutic treatment. The Nb4D group of CIBER-BBN and IQAC-CSIC (led by M.-Pilar Marco) has recently conducted a research to develop a highly sensitive, specific and reliable immunochemical assay to detect pyocyanin (PYO), one of the most important virulence factors[...]

01 Dec

Nanomedicine in the Medicine of the Future

Scientists of CIBER-BBN and NANBIOSIS ICTS have participated in the 4th Conference “Anticipating the Medicine of the Future”, which took place on November 30th, organized by the Roche Institute Foundation. The topics for this ediction had been identified by the Observatory of Trends in the Medicine of the Future: Pharmacogenomics, Nanomedicine and Epigenomic The event counted with three roundtables for discussion in relation to the three topics. The second one, on Nanomedicine, was moderated by Joaquín Arenas, Director of the Research Institute of the 12 de Octubre University Hospital. Ramón Martínez Máñez, Professor of Inorganic Chemistry at the Interuniversity Researc[...]

U2-Custom Antibody Service (CAbS)
• Read More

U3. Synthesis of Peptides Unit

Ciber bbn

U3. Synthesis of Peptides Unit

  • Scientific Director: Prof. Fernando Albericio albericio@ub.edu
  • Scientific Coordinator: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

U3. Peptides-Automatic synthesizer which can be operated at a range of scalesU3. Peptides-Automatic synthesizer which can be operated at a range of scales
U3. Peptides-System for acidolactic cleavage of the peptide resin boundby anhydrous HFU3. Peptides-System for acidolactic cleavage of the peptide resin boundby anhydrous HF

This Unit is coordinated by the Multivalent Systems for Nanomedicine goup at IQAC-CSIC and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio an Dra. Miriam Royo in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the IQAC-CSIC.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U3. Services & Rates

Equipments

In addition, this unit has access to:

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017		 Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

20 Jan

New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.

Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Multivalent self-assembled platforms for the delivery of chemotherapeutic drugs

Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Dr. Miriam Royo, who leads NANBIOSIS unit 3 of Synthesis of Peptide, explains one of the projects in which the ICTS is involved in relation with cancer therapy. The improvement of solubility and stability of clinically approved chemotherapeutic drugs still represent a big[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

27 Jan

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop.   Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development: U1 Protein Production Platform (PPP) at IBB-UABU3 Synthesis of Peptides Unit at IQAC-CSICU6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSICU20 In Vivo[...]

U3-Synthesis of Peptides Unit
• Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

    • Scientific Director: Prof. Nora Ventosa ventosa@icmab.es 
    • Scientific Coordinator: Dr. Mariana Köber mkober@icmab.es
    • Technical Coordinator: José Amable Bernabé jabernabe@icmab.es
    • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
    • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
    • Phone: +34 935 801 853
    • Fax: +34 935 805 729
    • Web: ICMAB

ICMAB CSIC

Order request

U6. Compressed fluids based biomaterials processing platformU6. Compressed fluids based biomaterials processing platform
U6. Dynamic light scattering for particle size and Z potential measurementsU6. Dynamic light scattering for particle size and Z potential measurements
U6. Compressed fluids based biomaterials processingU6. Compressed fluids based biomaterials processing

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana and Prof. Nora Ventosa, current directors of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties.  It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up.
The NANBIOSIS Unit 6 is works under the ISO9001 certification for standard quality control system
 




 




 



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE 
		
U6. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







GA: 720942

SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry
Unión Europea (Comisión Europea)
H2020-NMBP-2016-2017
Coordinator




SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







PI15/00272
Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.
Instituto de Salud Carlos III
Participant




H2020-MSCA-ITN-2014-642196
Integrated self-assembled SWITCHable systems and materials: towards responsive organic electronics - a multi-site innovative training action i-Switch
Unión Europea H2020
Participant




2014 SGR 17
Consolidation Research Group: Molecular Nanociènciai Materials Orgànics (NANOMOL)
Generalitat de Catalunya
Participant




CTQ2013-40480-R
Molecular Bio- and Electro-active materials for the improvement of health and social well-being (Be-Well)
MICINN
Participant




FP7-PEOPLE-2013-ITN nº 607721
Nanochemistry of molecular materials for 2-photon functional applications. Nano2Fun
Unión Europea
Participant




MAT2013-50036-EXP
Cell Surface Vessel Engineering Using Dynamic Molecular Bioinfecting (DYNAMO)
MINECO
Participant




RTC-2016-4567-1
Nanocapsules containing active ingredients for the topical treatment of dermatological diseases (NANO4DERM)
MINECO
Participant




RTC-2014-2183-S
Application of Quatsomes technology for the development of a new range of perfumed softeners with lower environmental impact
MINECO
Participant




201260E080
Self-assembly, Nanostructuring and Processing of Functional Organic Molecules and their Applications
Ministerio de Ciencia e Innovación
Participant




MAT2016-80826-R
Molecular materials and supramolecular organizations for therapy, diagnosis and tissue engineering (MOTHER)
MINECO
Participant




RTC-2014-2207-1
TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases
MINECO
Participant







		

		
Publications

		

			2016




    

  • Munoz-Gomez J.L., Monteagudo E., Lloveras V., Parella T., Veciana J., Vidal-Gancedo J.. Optimized polarization build-up times in dissolution DNP-NMR using a benzyl amino derivative of BDPA. RSC Advances. 2016;6(32):27077-27082.
    • 

  • Cordoba A., Hierro-Oliva M., Pacha-Olivenza M.A., Fernandez-Calderon M.C., Perello J., Isern B. et al. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials and Interfaces. 2016;8(18):11326-11335.
    • 

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
    • 

  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
    • 




		

		
		
	

		
		
News U6
12 May
NABIHEAL project launches website
The website for NABIHEAL, an EU-funded Horizon Europe project developing biomaterials for complex wound healing, is now online. The Horizon Europe project NABIHEALi project is coordinated by the Center for Biomedical Research Network (CIBER) at the Institute of Materials Science of Barcelona (ICMAB-CSIC). This project will apply one the “Cutting Edge Biomedical Solutions” of NANBIOSIS for the preparation of different nanoestructures with antimicrobial properties, required for the development of the final multifunctional wound healing biomaterials. This case will gather the expertise of two NANBIOSIS unit: NANBIOSIS U6 will produce and characterize these nanoestructures with antimicrobial properties, which will be tested in NANBIOSIS U16. Find out mor[...]
21 Mar
A discovery in one of the most aggressive cancers will allow more efficient diagnosis
The extracellular vesicles secreted by triple-negative breast cancer stem cells are markers of lung metastasis, according to a study carried out by researchers at CIBER. The work has been carried out by researchers from various CIBER-BBN groups (Bioengineering, Biomaterials and Nanomedicia), and CIBERONC (CIBER area focused on cancer) has participated in it. The research has been led by Joaquín Seras, from the Vall d’Hebron Research Institute (VHIR), a specialist in targeted drug therapies. Physicochemical EVs characterization and all the in vivo studies were performed by NANBIOSISunits of CIBER, specifically NTA analysis was carried out at Unit 6 of Biomaterial Processing[...]
20 Mar
Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior
Doctor Marc Martínez from the Nanomol-Bio group – NANBIOSIS U6 from CIBER-BBN at ICMAB-CSIC, defended his PhD thesis “Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior” on 9 March 2023 at ICMAB. he PhD thesis was supervised by Imma Ratera, Judith Guasch and Nora Ventosa from the Nanomol-Bio group at ICMAB-CSIC. Ana Paula Candiota Silveira, Scientific Coordinator of NANBIOSIS U25 was part of the Committee that evaluated the Thesis tooghether with Jesús Martínez de la Fuente, Instituto de Nanociencia y Materiales de Aragón (INMA-CSIC) (President),  and Anna Lagunas Targarona, Institut de Bioenginyeria de Catalunya (IBEC) (Vocal). As[...]
02 Feb
Advancing a novel nano-pharmaceutical towards clinical translation
Prof Nora Ventosa, Scientific Director of NANBIOSIS U6 “Biomaterial Processing and Nanostructuring Unit” from CIBER-BBN and ICMAB-CSIC) is hosting the Lecture on nano-pharmaceuticals: “Advancing a novel nano-pharmaceutical towards clinical translation” by Elisabet González, from Nanomol-Bio Group of ICMAB-CSIC and CIBER-BBN Monday, 13 February 202312 PM – 15 PMICMAB – Sala d’Actes Carles Miravitlles and ONLINE Registration and futher information Abstract: Nano-pharmaceuticals have the potential to drive the scientific and technological uplift, offering great clinical and socio-economic benefits to the society in general, industry and key stakeholders and patients. However, the translation of nano-pharmaceuticals from lab bench to an advanced stage of[...]
20 Jan
New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.
Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]
16 Jan
New European Project NABIHEAL in biomaterials for complex wound healing
The Horizon Europe project NABIHEAL, coordinated by the Center for Biomedical Research Network (CIBER) at the Institute of Materials Science of Barcelona (ICMAB-CSIC), was launched on 11-12 January 2023 in Barcelona with the first meeting of the international consortium, formed by 14 partners from 7 countries, including research centers, universities, and private companies.  This project will apply one the “Cutting Edge Biomedical Solutions” of NANBIOSIS for the preparation of different nanoestructures with antimicrobial properties, required for the development of the final multifunctional wound healing biomaterials. This case will gather the expertise of two NANBIOSIS unit: NANBIOSIS U6 will produce and[...]
24 Nov
“Preparation and characterization of SOFT Materials” Technical Seminar
Amable Bernabé, Tecnical Coordinator of NANBIOSIS U6: Biomaterial Processing and Nanostructuring Unit of CIBER-BBN and ICMAB-CSIC is giving a seminar on Preparation and Characterization of SOFT Materials. The seminar will tame place on Monday, 28 November 2020, at 12 PM at ICMAB in the Carles Miravitlles Seminar Hall, ” I will make a brief explanation about the equipment for the characterisation of particulate materials, type of samples that can be analysed, reports, etc… I will also talk about the equipment for processing materials with C” -explains Amable Bernabé.  Amable Bernabé joined the ICMAB-CSIC in 2004 as a research assistant working[...]
20 Oct
New edition of the course on characterization and preparation of particulate materials.
ICMAB-CSIC October 19th 2022 Amable Bernabé, from Nanbiosis U6 Biomaterial Processing and Nanostructuring Unit hosted from Monday, 3 October, to Wednesday, 5 October a course on “Characterization techniques for particulate materials”. The course counted with 10 participants from different CSIC centers. The course was an introduction to different techniques to characterize nanoparticles and other particulate matter, including the basic fundamentals of these techniques, sample preparation, practical examples and results interpretation.    It is the fifth edition of the course, which started in 2018. Amable Bernabé, technician from the Soft Materials Service, prepares and offers this course to all the CSIC community, so everyone who needs[...]

		
		
	

											

											U6-Biomaterial Processing and Nanostructuring Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U7. MicroFab & Microscopy Unit

												

		
		

		
		
	

		
		
Ciber bbn


U7. MicroFab & Microscopy Unit









IBEC






Order request

		
		
	

		
		
U7. Nanotechnology PlatformU7. Nanotechnology Platform
U7. Nanotechnology-PMMA surface with micro and nanostructures by e-beam lithographyU7. Nanotechnology-PMMA surface with micro and nanostructures by e-beam lithography
U7. Nanotechnology-Using photolitography to fabricate microfluidic devicesU7. Nanotechnology-Using photolitography to fabricate microfluidic devices


Description


The MicroFab & Microscopy Platform is part of the institute’s long-term strategic plan to create new Core Facilities in nanofabrication and bionanocharacterization. Currently, the platform is an accessible and versatile research facility featuring 150m2 of class 10,000 cleanroom space and laboratories offering state-of-the-art equipment for the fabrication and characterization of micro- and nanodevices and structures. Our aim is to facilitate advanced research by providing services in the fields of nanoscience and nanotechnology for all academic and industrial researchers. Some of the many areas of application include nanobioengineering, BioMEMS, materials science, tissue engineering, optic and biomaterials. IBEC’s Nanotechnology Platform offers scientific and technological support that includes the design, development and analysis of devices, materials, and processes, so that academic researchers and companies alike may use the platform to develop their innovative ideas.







		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U7. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017
Partner




PICCOLO-732111

Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support
European Commission-H2020
H2020-ICT-2016-1
Partner




0624_2IQBIONEURO_6_E

Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases
European Union Interreg : European Territorial Co-operation
POCTEP Interreg España-Portugal
Partner







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







TEC2015-70104-P
Microscrofidic 3D platform of Neuronal culture compartmentalized for the study of neurological diseases
MINECO
Others




COMRDI15-1-0013-09
Advancecat: acceleradora pel desenvolupament de terapies avançades
ACCIÓ
Participant







		

		
Publications

		

			2016


    

  • Lagunas A., Tsintzou I., Vida Y., Collado D., Perez-Inestrosa E., Pereira C.R. et al. Tailoring RGD local surface density at the nanoscale toward adult stem cell chondrogenic commitment. Nano Research. 2016;:1-13.
    • 




		

		
		
	

		
		
News U7
24 Oct
NANBIOSIS U7 at the 15th IBEC Symposium October 2022
The MicrofabSpace and Microscopy Characterization Facility of IBEC, U7 unit of Nanbiosis, presented a stand and posters in the 15 edition of the annual IBEC’s Symposium which took place last October 19th in Barcelona. Researechers of this facility showed new microfabrication processes and microscopy tools, to worldwide researchers in the field of bioengineering. The MicroFabSpace and Microscopy Characterization Facility is one of the most experienced services in the IBEC’s Core Facilities. With a cleanroom research space, specialized in the microfabrication and characterization of micro-structured devices focussed on bioengineering and a microscopy space specialized in the characterization of biological samples, it[...]
27 Jul
1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection
During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]
16 Sep
Microfluidic devices: The process of development
The development of microfluidic devices is very significant for in-vitro diagnostic devices, biomarkers and organ-on-a-chip applications. The techniques, the materials and the equipment used for the fabrication of these devices, are as important as the strategy followed to obtain them. And at the Nanotechnology unit of NANBIOSIS U7– (MicrofabSpace and Microscopy Characterization Facilities of IBEC), we own the tools, the know-how and the expertise to accomplish such a goal. We regularly guide the process of design, in collaboration with the final user, we customize the technology needed to get the product and complete the fabrication of the microfluidic device, drawing[...]
16 May
The importance of Nanomedicine and Bioengineering to address health challenges
Josep Samitier, Coordinator of the Nanomedicine Platform (NanoMed) and Director of IBEC, as well as Scientific Director of NANBIOSIS unit 7 of Nanotecnology, of IBEC and CIBER-BBN, particiated in the XIV Annual Conference of Biomedical Research Technology Platforms was held on 11 and 12 May. The Conference counted with the presence of relevant public and private sector actors, and more than 700 registered participants. During the opening ceremony, was opened, among others, by the Minister of Science and Innovation, Pedro Duque, it was precisely emphasized the importance of investment in science and technology. In the words of Josep Samitier: “The healt[...]
11 Feb
NANBIOSIS Scientific Women in the International Day of Women and Girls in Science
Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]
22 Jul
The Scientific Director of NANBIOSIS Unit 7, awarded with the Narcís Monturiol medal for his contribution to science and technology
The Catalan Government announced yesterday the Narcís Monturiol Medal award for scientific and technological merit to the Director of NANBIOSIS Unit 7 Nanotechnology Unit from CIBER-BBN and IBEC, Josep Samitier Martí, for his contribution to the development of the Catalan system of science and technology. The Narcís Monturiol Prize was established by the Generalitat of Catalonia in 1982, in honor of the Catalan scientist and inventor Narciso Monturiol, to award the people and entities that have made an outstanding contribution to the scientific and technological progress of Catalonia. It is awarded in the form of medals and plaques. The medals[...]
08 Jun
NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking
The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]
04 Dec
“Tips and tricks to achieve good results at the bench”
The IBEC Core Facilities team, coordinating NANBIOSIS U7 Nanotechnology Unit has celebrated the 6th edition of the Workshop “Tips and tricks to achieve good results at the bench”. This workshop is focused on fundamental basic aspects of working in a Chemistry/Biology laboratory: process of performing an experiment, from previous planning until the moment of leaving the bench. The workshop was divided in two parts: Introduction and overview to the Good Laboratory  Practices.Highly interactive and practical daily lab situations with real equipment. Upon completion of this workshop participants are able to understand the basics of good laboratory practices, plan an experiment[...]

		
		
	

											

											U7-Nanotechnology Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U8. Micro – Nano Technology Unit

												

		
		

		
		
	

		
		
Ciber bbn


U8. Micro – Nano Technology Unit


    

  • Scientific Director: Dr. Rosa Villa rosa.villa@imb-cnm.csic.es
    • 

  • Scientific Coordinator: Dr. Xavier Illa xavier.illa@imb-cnm.csic.es
    • 

  • Entities: Instituto de Microelectrónica de Barcelona – Centro Nacional de Microelectrónica (IMB-CNM, CSIC)
    • 

  • Address: Campus UAB, 08193, Cerdanyola del Vallés, Barcelona, Spain
    • 

  • Phone: +34 935 947 700 ext. 1208
    • 

  • Web: IMB – CNM, CSIC
    • 









CNM
CSIC






Order request

		
		
	

		
		
U8 MicroNanotechnology Unit..U8 MicroNanotechnology Unit..
U8 MicroNanotechnologyU8 MicroNanotechnology
U8-MicroNanotechnology-Unit-_c3U8-MicroNanotechnology-Unit-_c3


Description


This Micro-Nano Technologies Unit is located in the Microelectronic Institute of Barcelona, (IMB-CNM, CSIC) and it is coordinated by Dra Rosa Villa.


The unit has the capacity for producing high quality CVD-graphene and, thanks to the integration of the unit in the clean room facilities of the IMB-CNM, it is possible to complete a wide range of micro- and nanofabrication processes (thermal processes and CVD, metallization, photolithography, dry and wet etching, etc.) for the complete fabrication of graphene-based microdevices. The unit also comprises the equipment that allow the fabrication of such devices in flexible substrates like Polyimide and Parylene to build biocompatible implants and neuroprosthesis. In addition, the unit has the capacity for the encapsulation and electrical characterization of the fabricated devices.


The clean-room facility of the IMB-CNM is the largest installation with micro-nano technologies facilities in Spain. Its 1500 m2 Clean Room classes 10 to 10,000 are part of the MICRONANOFABS network, considered as Singular Scientific-Technical Infrastructure (ICTS).





		
Services

		

			



.


FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U8. Services & Rates

		
Equipments

		

			



.


Furthermore, in the IMB-CNM clean room (1500 m², Classes 10 to 10,000), there is also the following equipment, which is accessible under its own access policy:




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







GA: 696656



Graphene-based disruptive technologies — GrapheneCore1


Unión Europea (Comisión Europea)
H2020-Adhoc-2014-20
Partner




GA: 785219

Graphene Flagship Core Project-2 — GrapheneCore2’

’		
Unión Europea (Comisión Europea)
H202-SGA-FET-GRAPHENE-2017
Partner




GA: 649953

GRAPHENE FPA – FLAGSHIP - Graphene-based revolutions in ICT and beyond
Unión Europea (Comisión Europea)
H2020-FETFLAG-2014
Partner




SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







SAF2014-62114-EXP
RUPTURE OF THE HEMATORRETINIAN BARRIER: CAUSE OR CONSEQUENCE OF THE DIABETIC RETINOPATHY?
MINECO
Others




BIO2014-61377-EXP
BIOLIVER: THE DECONSTRUCTION APPLIED TO HEPATOLOGY
MINECO
Others




H2020-Adhoc-2014-20 - 696656
GrapheneCore1
European Commission
Participant




FP7-ICT-2013-FET-F - 604391
Neurographene: Neurological Recordings with Graphene
EUROPEAN COMISSION
Others




IMI Grant agreement No 115902
Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

Others







		

		
Publications

		

			2016


    

  • Moya A., Sowade E., del Campo F.J., Mitra K.Y., Ramon E., Villa R. et al. All-inkjet-printed dissolved oxygen sensors on flexible plastic substrates. Organic Electronics: physics, materials, applications. 2016;39:168-176.
    • 

  • Yeste J., Illa X., Gutierrez C., Sole M., Guimera A., Villa R.. Geometric correction factor for transepithelial electrical resistance measurements in transwell and microfluidic cell cultures. Journal of Physics D: Applied Physics. 2016;49(37):-.
    • 

  • Hernando A., Lazaro J., Gil E., Arza A., Garzon J.M., Lopez-Anton R. et al. Inclusion of Respiratory Frequency Information in Heart Rate Variability Analysis for Stress Assessment. IEEE Journal of Biomedical and Health Informatics. 2016;20(4):1016-1025.
    • 




		

		
		
	

		
		
News U8
03 Feb
“CIBER is collaboration”
CIBER Centro de Investigación Biomédica en Red (Consortium for Biomedical Research Network), one of the ICTS NANBIOSIS nodes to which 18 of its 26 units belong, presents the new institutional video “CIBER is Collaboration” This video puts a face to the scientific activity of CIBER researchers and highlights CIBER capacity for synergy. CIBER researchers speak about the main research lines of its 13 subject areas and highlights the collaboration between its more than 500 groups and more than 6,000 researchers belonging to more than 100 institutions of different natures that make up CIBER: hospitals, research centers, universities, foundations, etc. T[...]
25 May
“The almighty graphene”,  a podcast by Elisabet Prats
Elisabet Prats Alfonso, a researcher in the team coordinating NANBIOSIS U8 Micro– Nano Technology Unit explains in a podcast her most recent research based on the functionalization of chemical and biochemical sensor platforms as well as the characterization of materials such as graphene for both neuronal recording and biomarker detection. Her work is part of the Graphene Flagship project in which she collaborates with relevant European groups. Eli Prat as a researcher Ph.D. in Chemistry and also dedicated to dissemination is a great exemple for the NANBIOSIS aim to encourage STEAM scientific vocations especially among girls. In addition, she is[...]
07 Apr
Researchers of NANBIOSIS U8 highlighted in the World Health Day
In the Picture: Gemma Gabriel and Rosa Villa World Health Day is celebrated every year on 7 April (on the aniversary of the World Health Organization constitution) to raise awareness about the ongoing health issues that concern people across the world. This year, Xarctec Salud has called the attention on patients with brain diseases and spinal cord injuries and has highlighted the GAB Lab. Biomedical Applications Group of the IMB-CNM-CSIC and CIBER-BBN, the group, led by Rosa Villa, coordinates unit 8 ICTS NANBIOSIS of Micro-nano Technology Unit. https://youtu.be/wiA5oFc6Q48 The Xartec Salut is a network, led by CREB UPC, made up of 47[...]
07 Jan
New graphene-based neural probes improve detection of epileptic brain signals
A study published in Nature Nanotechnology shows that flexible brain probes made of graphene micro-transistors can be used to record pathological brain signals associated with epilepsy with excellent fidelity and high spatial resolution. This research was led by the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the University College London Queen Square Institute of Neurology (UK). The ability to record and map the full range of brain signals using electrophysiological probes will greatly advance our understanding of brain diseases and aid the clinical management of patients with diverse neurological disorders. However, current technologies[...]
23 Dec
The  suitability of flexible graphene depth neuralprobes for in vivo electrophysiology research
A study published in “Nature Nanotechnology” shows that flexible brain probes made of graphene micro-transistors can be used to record pathological brain signals associated with epilepsy with excellent fidelity and high spatial resolution. This research was led by the Catalan Institute of Nanoscience and Nanotechnology (ICN2), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the University College London Queen Square Institute of Neurology (UK). Barcelona, Wednesday 22 December 2021. The ability to record and map the full range of brain signals using electrophysiological probes will greatly advance our understanding of brain diseases and aid the clinical management of patients wit[...]
20 Jul
Inkjet printing technology is driving innovation of sensors for point-of-care devices
Miguel Zea, researcher at GAB Group –  Nanbiosis U8 Micro– Nano Technology Unit  will defend hir PhD thesis on Friday 23 of July, at 11 am, at the Graus Room of the Faculty of Sciences and Biosciences of the UAB about “Inkjet printing technology is driving the innovation of sensors for point-of-care devices” Thesis directors: Gemma Gabriel and Eloi Ramon Further information and registration for the event, onñine, here Abstract:  The ‘Inkjet printing’ technology is called to be the next generation of flexible electronics capable of performing functions that were only accessible with state-of-the-art microfabrication technologies. This is due, in part, to the versatility of digital,[...]
10 May
Collaboration in the CSIC White Paper “New Challenges in Biomedicine and Health”
The Spanish National Research Council (CSIC) is publishing the White Papers of the 14 strategic themes established on the basis of their scientific impact and social importance. The pen access to the White Paper of the fifth Challenge, Brain, Mind & Behaviour, is now avaailable. The book is the result of the “CSIC Scientific Challenges: Towards 2030”, in which the institution tackles the main issues and priorities for the future. This book is coordinated by Jesús Marco de Lucas and M. Victoria Moreno-Arribas. Drs. Rosa Villa and Anton Guimera (Biomedical Applications Group, GAB and NANBIOSIS U8 Micro– Nano Technology Unit from CIBER-BBN and IMB-CNM-CSIC)[...]
03 May
Collaboration in the CSIC White Paper “New Challenges in Biomedicine and Health”
The Spanish National Research Council (CSIC) is publishing the White Papers of the 14 strategic themes established on the basis of their scientific impact and social importance. The pen access to the White Paper of the fourth Challenge, New Challenges in Biomedicine and Health, is now avaailable. The book is the result of the “CSIC Scientific Challenges: Towards 2030”, in which the institution tackles the main issues and priorities for the future. This book is coordinated by Mario Delgado (Instituto de Parasitología y Biomedicina “López – Neyra”, Granada) and María Moros (Instituto de Nanociencia y Materiales de Aragón, Zaragoza). Drs. Rosa Villa (Biomedical Applications Group, GAB and[...]

		
		
	

											

											U8-Micro-Nano Technology Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U9. Synthesis of Nanoparticles Unit

												

		
		
Ciber bbn


U9. Synthesis of Nanoparticles Unit




    

  • 

      

    • Entities: Institute of Nanoscience of Aragón (INA)
      • 

    

    • 



    

  • 

      

    • Address: R&D Building, Campus Río Ebro, Universidad de Zaragoza. C/Mariano Esquirl S/n, 50018, Zaragoza, Spain
      • 

    

    • 



    

  • 

      

    • Phone: 34 976 761000 ext. 3496
      • 

    

    • 




 Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27.


Order request

		
		
	

		
		
U9. Synthesis of Nanoparticles- plasmonic nanoparticles 1U9. Synthesis of Nanoparticles- plasmonic nanoparticles 1
U9. Synthesis of Nanoparticles- hollow magnetic nanoparticlesU9. Synthesis of Nanoparticles- hollow magnetic nanoparticles
U9. Synthesis of Nanoparticles- Laser pyrolysis device and reaction areaU9. Synthesis of Nanoparticles- Laser pyrolysis device and reaction area


Description


This unit, integrated in the Nanostructured Films and Particles Group at the Institute of Nanoscience of Aragón (INA) coordinated by Dr. Jesús Santamaría, has as objective the synthesis of nanoparticles with applications in biomedicine. The unit provides an automated system for the synthesis of nanoparticles using laser-induced pyrolysis of chemical precursors in gas and/or aerosol phase, which enable either individual nanoparticles or biocompatible hybrid nanostructures to be produced in large quantities. In addition, this facility is able to draw on a wide range of nanoparticles fabrication technique, as well as having the necessary specialized personnel, to undertake exhaustive characterization of the microstructure, chemical composition, particles size and distribution of sizes, as well as magnetic, optical and colloidal properties and degree of biological functionality of the synthesized material.



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U9. Services & Rates

		
Equipments

		

			



In addition to this there is immediate access to advanced electron microscopies (SEM, TEM, HRTEM, UHRTEM), as well as other surface analysis and characterization equipment (XPS, XRD, FTIR, magnetic characterization). The equipment available makes this Unit unique to produce a wide variety of nanoparticles, , inorganic, polymeric, or multifunctional hybrid nanocomposites. 
		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017
Partner




PICCOLO-732111

Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support
European Commission-H2020
H2020-ICT-2016-1
Partner




0624_2IQBIONEURO_6_E

Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases
European Union Interreg : European Territorial Co-operation
POCTEP Interreg España-Portugal
Partner







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







CTQ2014-52384-R
INTELLIGENT APPLICATIONS BASED ON NANOSTRUCTURED FIBERS CONTAINING NATURAL BIOCIDES WITH PHARMACOKINETIC CONTROL OF THEIR RELEASE
Ministerio de Economia y Competitividad
Participant




CTQ2013-49068-C2-1-R
MICROSYSTEMS BASED ON NANOSTRUCTURES WITH SPECIFIC PROPERTIES OF ADSORPTION AND SUPERFICIAL PLASMON, FOR DETECTION OF HIDDEN EXPLOSIVES AND AGENTS OF CHEMICAL WAR.
Ministerio de Economia y Competitividad
Participant




TARMAC
TARMAC. New tools for the diagnosis and treatment of respiratory infectious diseases: pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistence
Ministerio de Economia y competitividad
Participant




TARMAC/IQMA-UDM-UPV
pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistence
CIBER-BBN-CIBERES-SEPAR
Participant




H2020-MSCA-ITN-2016/H2020-MSCA-ITN-2016
European Training Network for Continuous Sonication and Microwave Reactors.
Unión Europea
Participant




H2020-SPIRE-2014-2015 
ADREM / Adaptable Reactors for Resource- and Energy-Efficient Methane Valorisation
Unión Europea
Participant




I-2012/023
Development of a microfluidic platform to produce nanomaterials and assessment on new nanotechnology applications
Unión Europea
Participant




CTQ2016-77147-R
NEW STRATEGIES FOR CO2 CONVERSION USING CATALYSTS UNDER ELECTROMAGNETIC RADIATION.
MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD
Participant




CTQ2016-79419-R
ADVANCED ADSORPTION TECHNOLOGIES, SERS DETECTION AND CATALYSIS FOR CHEMICAL WAR
MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD
Participant




NANOHEDONISM
A photo-triggered on-demand drug delivery system for chronic pain
European Research Council
Participant




I-2011/004
HECTOR- MICROWAVE-ASSISTED MICROREACTORS: DEVELOPMENT OF A HIGHLY EFFICIENT GAS PHASE CONTACTOR WITH DIRECT CATAYST HEATING
Unión Europea
Participant




FIS PI15/01118
Towards an advanced therapy of bone regeneration: tissue intermediates activated by infrared energy for the controlled expression of osteogenic and angiogenic factors
INSTITUTO DE SALUD CARLOS III
Others




AMBIT
Animal Model of Bone Regeneration Induced by Tissue Intermediates Responsive to Near-Infrared Light
Roche Farma
Participant







		

		
Publications

		

			2016


    

  • Sebastian V., Smith C.D., Jensen K.F.. Shape-controlled continuous synthesis of metal nanostructures. Nanoscale. 2016;8(14):7534-7543.
    • 




		

		
		
	

		
		
News U9
11 Nov
Researchers of two NANBIOSIS units success in the Third Millennium Awards
Researchers of two NANBIOSIS units success in the Third Millennium Awards: the Young Research Talent award to Julia Ramirez (NANBIOSIS U27) and the Research and Future Award to the NFP group (NANBIOSIS U9) Last November 8, four initiatives received the highest award in the eighth edition of the HERALDO contest Third Millennium Awards which represent the recognition of the Aragonese community from the youngest to the most consolidated trajectories in knowledge transfer, innovation, and scientific dissemination. The Paraninfo of the University of Zaragoza hosted this event in which researchers CIBER-BBN – NANBIOSIS were recognised this year: The Films and Nanostructured[...]
27 Jul
1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection
During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]
02 May
Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé
During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]
17 Mar
Gold Nanoparticles Synthesized by NANBIOSIS U9 will destroy tumor cells without drugs
A CIBER-BBN team at the University of Zaragoza has developed intelligent shuttles (cell vesicles -exosomes-) to transfer nanoparticles to the interior of tumor cells and destroy them by means of heat and without drugs, following the “Trojan horse” strategy. “NANBIOSIS U9, “Synthesis of Nanoparticles Unit has developed the procedure to be able to internalize gold nanoparticles, with surface plasmon in the NIR electromagnetic range, inside extracellular vesicles derived from stem cells. The synthesis of the gold nanoparticles has been produced according to the synthesis procedures of UNIT 9 of the ICTS NANBIOSIS based on the galvanic substitution reaction in t[...]
04 Nov
Colloidal nanocrystals for energy applications
Semiconductors are materials used in a wide ranfe of applications since they are capable of capturing light and allowing us to take advantage of it. In addition, if we reduce its size to the nanometric scale we can activate additional very interesting properties On October 16, “Technoscience and Energy” took place in Inseec, Lyon (France), a science-industry transfer event between French and Spanish companies and researchers from the energy sector in France. Among the invited speakers was María Bernechea Navarro, ARAID Investigator, at the Institute of Nanoscience and Materials of Aragon at University of Zaragoza-INMA. In her talk, entitled “COLLOIDAL[...]
08 Jul
New project ExofluidTT for the production of nanovesicles using microfluidics applicable on Biomedicine
Víctor Sebastián Cabeza, researcher of NANBIOSIS U9 Synthesis of Nanoparticles of CIBER-BBN and the Institute of Nanoscience and Materials of Aragón, INMA, has obtained a research grant in the XX National Contest of the Ramón Areces Foundation in the category of Life and Matter Sciences with a funding of € 112,000 for the development in 3 years of nanovesicles using microfluidic technology. As explained by Victor Sebastian “the characterization of the nanovesicles will be carried with the equiment and expertise of NANBIOSIS Unit 9 The project entitled “Engineering of extracellular vesicles-exosomes using microfluidic technology for its application in biomedicine: ExoFluidTT”[...]
14 Jun
New drug delivery system for prolonged pain relief
The management of musculoskeletal pain is a key challenge due to the short duration of anesthetic effect produced by existing clinical treatments, in addition to their potential side effects. Researchers from the CIBER-BBN, the Institute of Nanoscience and Materials of Aragón (INMA), CSIC-University of Zaragoza and the Institute of Health Research of Aragón (IIS Aragón), in collaboration with researchers from the Faculty of Veterinary Medicine of the University of Zaragoza and with participation of NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit, have developed nanogels loaded with nanocrystals of bupivacaine (an anesthetic commonly used in epidural anesthesia and in the contro[...]
11 Feb
NANBIOSIS Scientific Women in the International Day of Women and Girls in Science
Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

		
		
	

											

											U9-Synthesis of Nanoparticles Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U10. Drug Formulation

												

		
		
Ciber bbn


U10. Drug Formulation


    

  • 

      

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
      • 

    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
      • 

    • Entities: Universidad del País Vasco (UPV/EHU)
      • 

    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
      • 

    • Phone: +34 653593042
      • 

    • Fax: +34 945 013040
      • 

    • Web: NANOBIOCEL UPV/EHU
      • 

    

    • 









UPV-EHU






Order request

		
		
	

		
		
U10. Drug Formulation-Particle_size_analyzerU10. Drug Formulation-Particle_size_analyzer
U10. Drug Formulation-LOTE 4 CALCEINA 10X 2BISU10. Drug Formulation-LOTE 4 CALCEINA 10X 2BIS
U10. Drug Formulation- Dissolution_rate_determination_equipmentU10. Drug Formulation- Dissolution_rate_determination_equipment


Description


Located at the Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Campus of Alava in Vitoria. The Unit is led by Prof. José Luis Pedraz and consists of large laboratories for cell culture, chromatography equipment, sample preparation and characterization, and one specific for scale preparation of pharmaceutical formulations. Recently the group has incorporated 3D bioprinters of the last generation with different technologies based on extrusion, inkjet, among others. It has also incorporated self-assembly equipment of nanoparticles based on microfluidic technologies.


This Unit can design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA, and vaccines using different methodologies based on micro and nano-medicine and the latter technology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this Unit. It counts on the most advanced equipment for micro and nanoencapsulation.


The Unit aims to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.


The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit10 counts with the most advanced equipment to cover the development for all the steps of the process.


One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency 



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U10. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







RTC-2016-4770-1

Development of a new bioadhesive for the treatment of Pterigium. Biotape


Ministerio de Economía, Industría y Competitividad (MINECO)
Retos Colaboración 2016
Partner




RTC-2016-5451-1

Development of Bioprinting and Bioink systems for cartilage and bone repair


Ministerio de Economía, Industria y Competitividad (MINECO)
Retos Colaboración 2016
Partner




GA: 783132

POSITION-II “A pilot line for the next generation of smart catheters and implants”


Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU
H2020-ECSEL-2017-1-IA-two-stage
Partner




GA: 645991

DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy
Unión Europea (Comisión Europea)
H2020-NMP-2014-two-stage
Partner




SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







RTC-2016-4770-1
DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD.
Participant




RTC-2016-5451-1
DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD.
Participant




RTC-2015-3303-1
Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS
MINISTERIO DE ECONOMIA Y COMPETITIVIDAD








		

		
Publications

		

			2016


    

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
    • 

  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
    • 

  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
    • 

  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
    • 

  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
    • 

  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.
    • 




		

		
		
	

		
		
News U10
23 Nov
Three articles acknoledging NANBIOSIS contribution awarded at the Bioaraba Research and Innovation Conference
Researchers of NANBIOSIS U10 “Drug Formulation” – NanoBiocel research group from CIBER-BBN and UPV/EHU receives 3 awards in the category of Best International Articles at the annual Bioaraba Research and Innovation Conference. On 4 November, the Bioaraba Health Research Institute held its XXIII Research and Innovation Conference in Vitoria. This important annual forum held in [...]
27 Oct
II Scientific Communication course
On October 18 and 19, was held the second course on Social Communication of Science, orgnized by NANBIOSIS U10 Drug Formulation Unit -(NanoBioCell Group of CIBER-BBN and UPV-EHU, this year entitled “Tools for the social communication of science“. The course aimed to provide doctoral students with communication with tools to be employed in their work [...]
09 Oct
The sprint of the European Project Moore4medical
The NanoBioCel group of the CIBER BBN, which also runs NANBIOSIS U10 Drug Formulation unit , organized the Workshop #6 of the Moore4medical European project at the Alava Technology Park on October 4, 5 and 6 The Central Building of the Álava Technology Park hosted the ‘Workshop #6’ of the European project which. 80 people [...]
29 Apr
CRISPR technologies for Cystic Fibrosis treatment
Cystic fibrosis is an inherited genetic disease that mainly affects the lungs and the digestive system On April 6, the first meeting was held, on the one hand, with people with Cystic Fibrosis and the Euskadi Cystic Fibrosis Association (Arnasa) and, on the other, with the NanoBioCel research group of the CIBER-BBN and the University [...]
05 Apr
1st Meeting with Cystic Fibrosis Patiens (NanoBioCel -ARNASA)
Cystic Fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is a genetic, degenerative and chronic disease, with a population incidence is 1 in 5,000, so it is considered among the so called “Rare Diseases” The most common symptoms are continuous colds, repeated infections, decreased lung capacity, impossibility of fat absorption and [...]
22 Mar
The results of POSITION II highlighted by CORDIS: A pan-European alliance for the next generation of smart catheters
In the picture: microencapsulated cardiospheres 10X Captured Brightfield with DM_RGB_Brightfield with DM The European project POSITION-II has been selected for publication in the ‘Results in Brief’ section of the Community Research and Development Information Service (CORDIS) website. CORDIS is the European Commission’s primary source of results from the projects funded by the EU’s framework programmes [...]
15 Feb
AWARDS of the Academy of Pharmacy of Castilla y León 2021 to  researchers from NANBIOSIS U10
The leader of the NanoBioCell Group form CIBER-BBN and UPV/EHU, Jose Luis Pedraz, and the reaearches Laura Saenz del Burgo and Markel Lafuente have received the 2021 Award from the Academy of Pharmacy of Castilla y León, on February 4, at the city ​​of Salamanca, for the work entitled: “Design and Characterization of a biotin [...]
13 Jan
Best Emergeging Researcher Award  in the Biomedical Area to Edorta Santos
Edorta Santos Vizcaíno has been awarded as Best Emerging Researcher in the biomedical area by the Bioaraba Health Research Institute in the XXII edition of the Research and Innovation Conference. This award aims to recognize the work of researchers under the age of 40 who carry out their research activity in any public center of [...]
26 Nov
New Equipment available for the Regenerative Medicine Research Line of the U10 of NANBIOSIS
The Unit 10 of Drug Formulation of the ICTS NANBIOSIS coordinated by the CIBER-BBN NanoBioCel group directed by Jose Luis Pedraz, which belongs to the University of the Basque Country, has been present at the signing of the agreement that gives support by the Provincial Council of Alava within the framework of the Advance Pharma [...]
14 Oct
Results of the POSITION-II Project “A pilot line for the next generation of smart catheters and implants”
Cáceres, October 14th, 2021 POSITION II has received funding within the Electronic Components and Systems for European Leadership Joint Undertaking (ECSEL JU) in collaboration with the European Union’s H2020 Framework Programme (H2020/2014-2020) and National Authorities, under grant agreement Ecsel-783132-Position-II-2017-IA. It promotes innovation in smart medical instruments and focuses in the next generation of smart catheters [...]

		
		
	

											

											U10-Drug Formulation											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U12. Nanostructured liquid characterization unit

												

		
		
Ciber bbn


U12. Nanostructured liquid characterization unit


    

  • 

      

    • Scientific Director: Prof. Carlos Rodríguez cranqb@cid.csic.es
      • 

    • Scientific Coordinator: Jordi Esquena jemqci@iqac.csic.es
      • 

    • Entities: Colloid and Interfacial Chemistry Group (QCI) at the Institute of Advanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
      • 

    • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
      • 

    • Phone: +34 934 006 159
      • 

    • Web: QCI – IQAC- CSIC
      • 

    

    • 














IQAC
CSIC








Order request

		
		
	

		
		
U.12 – Reometro_2U.12 – Reometro_2
U.12 – tensiometro_2U.12 – tensiometro_2
U.12 – Espectrofotometro_2U.12 – Espectrofotometro_2


Description


The unit is located at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), in Barcelona and it is coordinated by the Colloidal and Interfacial Chemistry Group, led by Dr. Carlos Rodríguez. The unit is focused on the characterization of nanostructures in liquids and liquid/liquid interfaces, such as micelles, liposomes, micro- and nano-emulsions, and nanoparticles. The unit features state-of-the-art instrumentation for the determination of various parameters such as size distribution and zeta potential (surface charge), critical micelle concentration (CMC), solubilization capacity, osmolarity, surface and interfacial tension, wettability, refractive index, turbidity, colloidal stability, density, viscosity and other rheological parameters (shear and elastic moduli, critical yield stress, etc.)


The Unit 12 has implemented and mantein the ISO9001 certification forstandard quality control system.


 IQNet ISO 9001:2015 Certification 


 AENOR ISO 9001:2015 Certification 



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE 
		
U12. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017
Partner




PICCOLO-732111

Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support
European Commission-H2020
H2020-ICT-2016-1
Partner




0624_2IQBIONEURO_6_E

Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases
European Union Interreg : European Territorial Co-operation
POCTEP Interreg España-Portugal
Partner







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







CTQ2014-52687-C3-1-P
Design and applications of new biocompatible micro / nanogels obtained by advanced condensation methods (MICRONANOGELES)
MINECO
Participant




2014SGR1655
Grants for consolidated Research Groups of Catalonia
Generalitat de Catalunya
Participant




FP7-PEOPLE-2013-ITN - 606713
Biopolymer Based FOOd Delivery Systems (BIBAFOODS)
Unión Europea
Participant




Plan de Actuación 2015
Agreement of ACC1Ó with the UAB, the PRUAB, the CSIC and the CVC for the promotion of the technological transfer
Generalitat de Catalunya
Participant




TECSPR14-2-0033 
Theranostic Magnetic Nanoparticles For Cancer Diagnosis and Treatment: Magnetic Properties and Controlled Release of Anticancer Drugs (TheraMagNano)
Unión Europea
Participant




TECSPR14-2-0044
Novel antimicrobial hydrogels for contact lenses (HYDROLENSES)
Unión Europea
Participant




Acción COST CM1101
Joint Meeting of WG 3 and WG 4. Workshop "Nano-biocolloidal materials and non-equilibrium self-assembly"
Unión europea
Participant




Ref.: 308810 076/2015 
DEVELOPMENT OF INNOVATIVE FORMULATIONS FOR THE DELIVERY OF ACTIVITIES INTO THE SKIN (ES)
ALMIRALL
Participant







		

		
Publications

		

			2016


    

  • Fornaguera C., Caldero G., Solans C.. Electrolytes as a tuning parameter to control nano-emulsion and nanoparticle size. RSC Advances. 2016;6(63):58203-58211.
    • 

  • Caldero G., Montes R., Llinas M., Garcia-Celma M.J., Porras M., Solans C.. Studies on the formation of polymeric nano-emulsions obtained via low-energy emulsification and their use as templates for drug delivery nanoparticle dispersions. Colloids and Surfaces B: Biointerfaces. 2016;145:922-931.
    • 

  • Fornaguera C., Feiner-Gracia N., Caldero G., Garcia-Celma M.J., Solans C.. PLGA nanoparticles from nano-emulsion templating as imaging agents: Versatile technology to obtain nanoparticles loaded with fluorescent dyes. Colloids and Surfaces B: Biointerfaces. 2016;147:201-209.
    • 

  • Magana J.R., Kolen’Ko Y.V., Deepak F.L., Solans C., Shrestha R.G., Hill J.P. et al. From Chromonic Self-Assembly to Hollow Carbon Nanofibers: Efficient Materials in Supercapacitor and Vapor-Sensing Applications. ACS Applied Materials and Interfaces. 2016;8(45):31231-31238.
    • 

  • Perez-Carrillo L.A., Vilchez S., Mosa J., Aparicio M., Castro Y., Duran A. et al. Synthesis and properties of TiO2-P2O5 and SiO2-TiO2-P2O5 porous hybrids obtained by templating in highly concentrated emulsions. Ceramics International. 2016;42(16):18965-18973.
    • 




		

		
		
	

		
		
News U12
15 Nov
Happy Day of Chemistry! The  role of Chemistry in a sustainable research in health
Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]
27 Jul
1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection
During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]
03 May
OPEN SUBMISSION FOR JOURNAL SPECIAL ISSUE ON OLIGONUCLEOTIDE BASED THERAPIES
Dr. Ramon Eritja, Scientific Director of NANBIOSIS unit 29 of Oligonucleotide Synthesis Platform (OSP) and Dr. Santiago Grijalvo researcher at NANBIOSIS unit 12 of Nanostructured liquid characterization, from CIBER-BBN and IQAC-CSIC, together with Dr. Andreia F. Jorge, from Coimbra Chemistry Centre (CQC), acting as guest editors of journal Pharmaceutics, of MDPI Publisher, welcome authors to submit their articles on special issues on Recent Trends in Oligonucleotide Based Therapies. In the past few decades, significant efforts have been made towards the clinical application of oligonucleotides. However, the potential of the therapeutic applications of RNA-based strategies have recently been spotlighted after the first approval of mRNA vaccines in response to COVID-19[...]
02 May
Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé
During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]
31 Mar
Colloidal phenomena in COVID-19
Transmission electron microscope image of SARS-CoV-2 (National Institute of Allergy and Infectious Diseases https://www.niaid.nih.gov) The special volume (No. 55) of the journal Current Opinion in Colloid and Interface Science reviews the implications of colloidal science in the phenomenology of COVID-19, for which the techniques available in NANBIOSIS U12, “Nanostructured liquid characterization unit” , are relevant. Two articles to highlight in this special volume: Airborne transmission of the virus through droplets, and the effect of evaporation and sedimentation. Airborne transmission is determined by the settling time, that is, the time it takes for droplets to be in the air before settling.[...]
18 Oct
ISO 9001-2015 Quallity Management Certification  for NANBIOSIS U12
NANBIOSIS U12 “Nanostructured liquid characterization unit” of IQAC-CSIC and CIBER-BBN, led by Dr. Carlos Rodriguez Abreu and D. Jordi Esquena, has implemented a Quality Management System for the scope of Technological service for characterization of colloidal dispersions, which fulfills the requirements of the standard ISO 9001:2015. An IQNet recognized certificate has been issued by AENOR last week. This certification will expand and consolidate the service  that Unit 12 of NANBIOSIS is giving to companies and public sector researchers and facilitate their integration in cooperative international projects. The ISO 9001 Standard is the most widespread Quality Management tool worldwide, with over[...]
20 Sep
The European Researcher’s Night with NANBIOSIS’ scientists.
The European Researchers’s Nigth is a public event dedicated to the dissemination of science that is held every year in more than 300 cities in 30 countries of Europe at the same time, organized on the last Friday and Saturday of September. This year face-to-face activities are progrmmed in different locations of Catalonian cities and also the “Nit de la Recerca” YouTube channel offers more than 20 noves microxerrades led by researchers from Catalonia. Two NANBIOSIS’ researchers have joined this event to explain their research: Julian Guercetti – Nb4D Group – NANBIOSIS U2 CAbS, from IQAC-CSIC and CIBER-BBN, will giv[...]
05 May
Practical Sessions in the Master of Cosmetic and  Dermopharmacy by NANBIOSIS U12
The researchers of NANBIOSIS U12, Nanostructured liquid characterization unit of CIBR-BBN and IQAC-CSIC, will participate in teaching and training students of the Master en Cosmética y Dermofarmacia, organized by Centro de Estudios Superiores de la Industria Farmacéutica (CESIF), from 17 May to 16 June 2021. Cosmetic manufacturing companies are committed to innovation, both in technological development and in the use of components in their formulations, adapting to new trends and user needs. Determination of colloidal stability, surface tension, particle size and rheological behaviour, among many others properties, is essential for the proper characterization and understanding the performance of cosmetic products.[...]

		
		
	

											

											U12-Nanostructured liquid characterization unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U14. Cell Therapy

												

		
		
JUMISC


U14. Cell Therapy


    

  • Scientific Director: Dra. Esther López Nieto elopez@ccmijesususon.com
    • 

  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
    • 

  • Address: Carretera N-521, km 41, 10071 Cáceres
    • 

  • Phone: + 34 927 181 032
    • 

  • Web: JUMISC
    • 



Order request

		
		
	

		
		
U.14. Cell TherapyU.14. Cell Therapy
U.14. Cell TherapyU.14. Cell Therapy
U.14. Cell Therapy  unitU.14. Cell Therapy  unit


Description


Laboratory with an area of 81,02 m2 for cell biology and molecular biology techniques. The laboratory is also equipped with two cell culture rooms for the isolation, expansion and characterization of different cell types.



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
Unit 14. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017
Partner




PICCOLO-732111

Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support
European Commission-H2020
H2020-ICT-2016-1
Partner




0624_2IQBIONEURO_6_E

Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases
European Union Interreg : European Territorial Co-operation
POCTEP Interreg España-Portugal
Partner







		

		
		
	

											

											U14-Cell Therapy											

												
												•
												Read More